ClinicalTrials.gg
RecruitingNCT07120698CTONG 2508Updated Jan 5, 2026

Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)

A Phase 2 interventional study of Sintilimab in NSCLC (Non-small Cell Lung Cancer), MRD and II-IIIB Stages, sponsored by Guangdong Association of Clinical Trials. Recruiting at 2 sites in China. Open to participants aged 28 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Guangdong Association of Clinical Trials · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
115
Allocation
Not applicable
Ages
28 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies testing sintilimab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 21 under way, 4 of them phase 3. sintilimab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
11th of 45
115 · median 60
Started
2025
with 5 others
Phase 2
32 of 45
12 open now
Primary completion
2029-06
later than 20 of 20 live
Registered
42nd of 45
by date
Lead sponsor
3 of 45
Guangdong Association of Clinical Trials

Among the 45 studies testing sintilimab in Carcinoma, Non-Small-Cell Lung, this one is the 11th largest by planned enrollment, is one of 6 that started in 2025, is one of 32 in phase 2, reaches primary completion later than 20 of the 20 other live ones, and was the 42nd registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 45 studies testing sintilimab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

About sintilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 28 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing sintilimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a multicenter, prospective, open-label Phase II study designed to evaluate the safety and efficacy of adjuvant sintilimab therapy guided by minimal residual disease (MRD) in patients with Stage II-IIIB non-small cell lung cancer (NSCLC) who have not achieved a pathological complete response (non-pCR) after neoadjuvant immunotherapy combined with chemotherapy. The study is being conducted at the Third People's Hospital of Chengdu and the Guangdong Provincial People's Hospital.

Read the detailed description

Patients with Stage II-IIIB NSCLC who have not achieved a pathological complete response after neoadjuvant immunotherapy combined with chemotherapy will be enrolled in this study. Eligible patients will receive adjuvant sintilimab therapy guided by MRD.

Patients should undergo a test 3 to 7 days after surgery, and another test 28 days (±3 days) after. surgery The results of these two tests will be used to determine the subsequent treatment pathway. Participants with two consecutive positive MRD test results or a single positive MRD test result will be included in the MRD + treatment cycle: they will receive adjuvant therapy with sintilimab (200 mg, intravenous infusion, every 3 weeks). Follow-up will be conducted every 3 months, during which chest CT scans and MRD tests will be performed. If the MRD test result turns negative, treatment will be discontinued and participants will be monitored. If the MRD test result remains positive, sintilimab treatment will continue.

Participants with two consecutive negative MRD test results will be included in the MRD - treatment cycle: they will only receive follow-up observation. Follow-up will be conducted every 3 months, during which chest CT scans and MRD tests will be performed. If the MRD test result turns positive, adjuvant therapy with sintilimab (200 mg, intravenous infusion, every 3 weeks) will be initiated. If the MRD test result remains negative, follow-up observation will continue.

The maximum number of treatment cycles for sintilimab therapy is 18 cycles. Safety will be evaluated through adverse events (AE) and laboratory tests.

03

Conditions studied

  • NSCLC (Non-small Cell Lung Cancer)
  • MRD
  • II-IIIB Stages
  • Adjuvant Immunotherapy

Keywords

  • MRD
  • II-IIIB stages
  • NSCLC (non-small cell lung cancer)
  • adjuvant immunotherapy
04

Who can participate

Ages eligible
28 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed written prior to the initiation of any trial-related procedures.
  2. Male or female aged ≥18 years and ≤75 years.
  3. or cytologically confirmed non-small cell lung cancer (NSCLC).
  4. Received 3-4 cycles of immunotherapy ( inhibitor) combined with chemotherapy.
  5. Underwent radical surgical treatment (R0), with surgical procedures including lobectomy or sleeve lobectomy. All gross tumors must be completely resected at the end of surgery, and all surgical margins of the resected tumors must be negative. Systemic lymph node dissection is required.
  6. Clinical stage II, IIIA, or IIIB (limited to resectable N2) according to the AJCC 8th edition TNM classification for lung cancer. Resectable N2 refers to non-massive (defined as short-axis diameter \<3 cm), discrete, or single-station N2 involvement. If clinically suspected of N2 or N3, pathological confirmation is recommended whenever feasible.
  7. Patients with pathological response assessment of 1%-90% residual viable tumor (RVT).
  8. No EGFR mutations, ROS1 fusions, ALK fusions, or RET fusions. Other potentially targetable driver gene alterations will be determined in consultation with the sponsor.
  9. No prior anti-tumor treatment other than PD-1 inhibitors and chemotherapy before radical surgery for lung cancer.
  10. Completed radical surgery for lung cancer 4-12 weeks prior to study enrollment, with pathological confirmation of R0 resection and radiological evidence of no residual tumor foci 1 month after radical surgery.
  11. (ECOG) performance status of 0-1.
  12. >6 months.
  13. Adequate organ function:

1. (ANC) ≥1.5×10\^9/L without the use of granulocyte colony-stimulating factor within the past 14 days.

2. ≥100×10\^9/L without transfusion within the past 14 days. 3. >9 g/dL without transfusion or use of erythropoiesis-stimulating agents within the past 14 days.

4. Total ≤1.5× (ULN). 5. (AST) and alanine aminotransferase (ALT) ≤2.5×ULN (subjects with liver are allowed to have ALT or AST ≤5×ULN).

6. Serum creatinine ≤1.5×ULN and (calculated using the Cockcroft-Gault formula) ≥60 ml/min.

7. Good coagulation function, defined as (INR) or prothrombin time (PT) ≤1.5×ULN.

8. Normal thyroid function, defined as thyroid-stimulating hormone (TSH) within the normal range. Subjects with baseline TSH outside the normal range are eligible if total T3 (or free T3) and free T4 are within the normal range.

9. Cardiac enzyme profile within the normal range (subjects with isolated laboratory abnormalities deemed not by the investigator are also eligible).

14. For female subjects of , a negative urine or serum pregnancy test must be obtained within 3 days prior to the first administration of the study drug (Day 1 of Cycle 1). If the urine pregnancy test result is inconclusive, a serum pregnancy test is required. women are defined as those who have been amenorrheic for at least 1 year, or those who have undergone surgical sterilization or hysterectomy.

15. All subjects (regardless of gender) at risk of conception must use with a failure rate of less than 1% per year throughout the treatment period until 120 days after the last administration of the study drug (or 180 days after the last administration of chemotherapy).

16. Provide samples for MRD assessment (surgical tissue + blood).

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of any other than non-small cell lung cancer within 5 years prior to the first dose (excluding completely treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or carcinoma in situ that has been completely resected).
  2. Received radiotherapy prior to dosing.
  3. Patients who underwent pneumonectomy.
  4. Currently participating in an interventional clinical study or received other drugs or used investigational devices within 4 weeks prior to the first dose.
  5. Received neoadjuvant treatment with anti-tumor therapies other than chemotherapy and immunotherapy.
  6. Presence of unhealed surgical incisions, ulcers, or fractures.
  7. In the investigator's opinion, severe concomitant systemic diseases that may affect the subject's ability to complete the study. Subjects with positive antibodies must be assessed and confirmed by the investigator to have no autoimmune diseases requiring systemic treatment before enrollment.
  8. Presence of primary immunodeficiency diseases.
  9. Receiving systemic therapy within 7 days prior to the first dose of the study (excluding intranasal, inhaled, or other topical corticosteroids). Note: The use of physiologic doses of corticosteroids (≤10 mg/day prednisone or equivalent) is permitted.
  10. Known allogeneic organ transplantation (excluding corneal transplantation) or hematopoietic stem cell transplantation.
  11. Known allergy to the active ingredient or of the study drug, sintilimab.
  12. Not fully recovered from toxicities and/or complications caused by any prior interventions prior to the start of treatment (i.e., ≤Grade 1 or returned to baseline, excluding fatigue or alopecia).
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
115 participants (estimated)

Study arms

  • Experimental
    Experimental arm

    sintilimab

    Drug: Sintilimab

Interventions

  • Patients who met the inclusion criteria were treated with adaptive adjuvant sintilimab therapy guided by MRD. Patients should test twice at postoperative days 3 to 7 and again at postoperative day 28 (±3 days). The results of these two tests will be used to determine the subsequent treatment pathway. Participants with two consecutive positive MRD tests or a single positive MRD test will be enrolled in the MRD+ treatment cycle:they will receive adjuvant treatment with sintilimab (200 mg, intravenous infusion, every 3 weeks). Follow-up visits will be conducted every 3 months, during which chest CT scans and MRD testing will be performed. If MRD becomes negative, treatment will be discontinued and the participant will be monitored. If MRD remains positive, treatment with sintilimab will continue. Participants with two consecutive negative MRD tests will be enrolled in the MRD- treatment cycle:they will undergo follow-up observation only. Follow-up visits will be conducted every 3 months

06

What researchers measure

Primary outcomes

  1. 2-year EFS rate

    Event-free survival (EFS) is defined as the time from the date of randomization (or the start of treatment) to the first occurrence of any of the following events: disease progression, local or distant recurrence, or death due to any cause. If a patient does not experience any of these events within 2 years, they are considered to have achieved 2-year EFS.

    Time frame: 2 year after treatment initiation

Secondary outcomes

  1. mEFS

    The median Event-Free Survival (mEFS) is defined as the median time from the date of randomization or the initiation of treatment to the first occurrence of a prespecified event, such as disease progression, death, or change in treatment regimen.

    Time frame: From enrollment to disease progression, reoccurrence, or death due to any cause. (Up to a median of 30 months)

  2. 2-year OS rate

    The 2-year Overall Survival (OS) rate is defined as the proportion of patients who remain alive at the specific time point of 2 years from the date of randomization or the initiation of treatment.

    Time frame: 24 months

  3. mOS

    The median overall survival (mOS) is defined as from date of enrollment until the date of first documented date of death from any cause, whichever came first, assessed up to 40 months, at which the survival rate is 50%.

    Time frame: OS is defined as the time from enrollment to death, regardless of disease recurrence, assessed up to 100 months

  4. AEs

    Safety and tolerability will be assessed by the incidence of adverse events (AEs), serious adverse events (SAEs), immune-related adverse events (irAEs), deaths, and laboratory abnormalities.

    Time frame: 24 months

  5. QoL

    Per physician's discretion, the patient will complete one or more of the following QoL instruments: EQ-5D is a 5 item questionnaire with a total score ranging from 0 to 100 with the higher score indicating greater satisfaction, EORTC QLQ-C30 is a 30 item questionnaire with a total score ranging from 1 to 4 with the lower score indicating greater satisfaction.

    Time frame: 24 months

Other outcomes

  1. Analyze the proportion of the four types of pathological response (1%-5% irRVT vs. >5%-30% irRVT vs. >30%-80% irRVT vs. >80% irRVT) and their correlation with median event-free survival (mEFS).

    Proportion of the four types of RVT results Assessment of the relationship between different RVT results and median event-free survival (mEFS)

    Time frame: From enrollment to disease progression, reoccurrence, or death due to any cause. (Up to a median of 30 months)

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — We will not share individual participant data (IPD) because the original informed-consent forms signed by participants did not explicitly cover secondary use of their data by external parties, and thus sharing IPD would risk violating the approved ethics agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jun 2029, 43 months after the start.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 43 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2025
First posted
Aug 13, 2025
StartActual
Nov 5, 2025
Primary completionEst.
Jun 26, 2029
CompletionEst.
Jul 26, 2029
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07120698
Lead sponsor
Guangdong Association of Clinical Trials
Collaborators
Zunyi Medical College, Suining Central Hospital, Shenzhen Second People's Hospital, Guangdong Provincial People's Hospital
Responsible party
Yi Yang (chief physician, Guangdong Association of Clinical Trials) — Principal investigator
First posted
Aug 13, 2025
Start date
Nov 5, 2025
Primary completion
Jun 26, 2029 (estimated)
Completion
Jul 26, 2029 (estimated)
Last update
Jan 5, 2026

Study contacts

Yi Yang
Contact
cd3yyyy@126.com
+8613980013944
Benyuan Jiang
Contact
jiangbenyuan@gdph.org.cn
15918748727
Yang
principal investigator · Guangdong Association of Clinical Trials

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sintilimab

Start the discussion